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Abstract
Research suggests that individuals’ expectations about a drug’s effects are predictive of various
types of substance abuse, including nonmedical prescription stimulant use (Torrealday et al.,
2008). Nonmedical prescription stimulant use, or NMPSU, refers to any use of prescription
stimulants without a medical prescription, use of prescription stimulants for nonmedical
purposes, or use that exceeds what is prescribed (Bavarian, Flay, Ketcham, &Smit, 2013).
NMPSU is associated with a number of negative outcomes, including drug and alcohol abuse,
risk-taking behavior, mental illness, physical health problems, and lower educational attainment
(McCabe, Teter, Boyd, & Wechsler, 2005). While most previous research has focused on college
students, there is evidence that medical students are also at high risk for NMPSU (Emanuel et al.,
2013; McNiel et al., 2011). This dissertation study investigated the usefulness of the Prescription
Stimulant Expectancy Questionnaire–II (PSEQ–II) in identifying and classifying different types
of prescription stimulant users in the medical student population. The results suggest that the
PSEQ–II can effectively discriminate between users and nonusers in the medical student
population, but not between medical and medical/nonmedical users. In addition, the results
indicate that medical students’ expectancies about cognitive enhancement and anxiety and
arousal correlate with past prescription stimulant use, even when ADHD symptoms are
controlled for. These findings should help inform preventions and interventions for NMPSU in
the medical student population.
Keywords: prescription stimulants, expectancies, medical students, ADHD, PSEQ–II

This dissertation is available in open access at AURA: Antioch University Repository and
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PRESCRIPTION STIMULANT USE AMONG MEDICAL STUDENTS

2

Expectancies as a Predictor of Prescription Stimulant Use Among Medical Students
The following dissertation study investigated the usefulness of the Prescription Stimulant
Expectancy Questionnaire–II (PSEQ–II) in understanding the expectancies and prescription
stimulant use habits of medical students. Research suggests that past and future drug use can be
predicted by individuals’ expectancies, or their expectations about a drug’s effects or
consequences (Looby & Earleywine, 2010). The following study is a replication of an earlier
study by Looby and Earleywine (2010), which suggested that the PSEQ–II can reliably predict
past and future prescription stimulant use and classify individuals as medical or nonmedical
users based on their expectancies. However, rather than sampling an educationally diverse group
of adults, this study specifically examined full-time medical students, who may be at greater risk
for NMPSU (Emanuel et al., 2013; McNiel et al., 2011). In addition, in order to obtain a more
selective sample, participants were recruited through Amazon Mechanical Turk rather than
Craigslist, as in the original experiment. The results of this study provide insight into the
relationship between medical students’ expectancies and their prescription stimulant use habits.
Literature Review
Over the past few decades, prescription stimulant use has surged in the United States
(DeSantis & Hane, 2010). Prescription stimulants are a class of drugs commonly used in the
treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and include amphetamines (e.g.,
Adderall), dextroamphetamines (e.g., Dexedrine), and methylphenidates (e.g., Ritalin; DeSantis
& Hane, 2010). Because of their high potential for abuse and misuse, prescription stimulants are
currently classified as Schedule II drugs in the United States (DeSantis & Hane, 2010). They are
only available by prescription, dispensed one month at a time, and not refillable (DeSantis &
Hane, 2010). Despite strong attempts at regulation, the diversion of prescription stimulants to
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individuals without valid medical prescriptions has increased dramatically in recent years
(Pilkinton & Cannatella, 2012).
Nonmedical prescription stimulant use. Nonmedical prescription stimulant use
(NMPSU) is defined as any use of prescription stimulants without a medical prescription, use of
prescription stimulants for nonmedical purposes, or use that exceeds what is prescribed
(Bavarian et al., 2013). NMPSU is associated with a variety of negative psychological outcomes,
including (a) depression; (b) anxiety; (c) stress, alcohol, and drug abuse; and (d) risk-taking
behaviors (Gomes, Song, Godwin, & Toriello, 2011; Sussman, Pentz, Spriujt-Metz, & Miller,
2006; McCabe et al., 2005). Studies of college students suggest that NMPSU is associated with
lower grade point averages and lower academic achievement (McCabe et al., 2005). Prescription
stimulant abuse also places individuals at risk for a variety of physical health consequences,
including insomnia, seizures, cardiovascular problems, and even sudden death (Gomes et al.,
2011). As NMPSU has increased, so has the number of emergency room visits involving
prescription stimulants, which more than doubled between 2005 and 2010 (Bavarian et al.,
2013).
Recent research estimates that between 7% and 21% of the general population will
engage in NMPSU at some point in their lifetime (Ford & Schroeder, 2009). Nonmedical
prescription stimulant use is most prevalent among (a) Caucasians, (b) males, (c) people ages
18–25, (d) varsity athletes, (e) persons of high socioeconomic status, (f) sorority and fraternity
members, (g) students at colleges with competitive admission standards, and (h) students in the
Northeast region of the United States (McCabe, Teter & Boyd, 2005; Dussault & Weyandt,
2013). Nonmedical prescription stimulant use is also common among adults enrolled in medical
school, dental school, pharmacy school, and other rigorous graduate programs (Pilkinton &
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Cannatella, 2012; McNiel et al., 2011; Tuttle, Scheurich, & Ranseen, 2010).
Research suggests that the majority of individuals who engage in NMPSU do so for
academic reasons (Hartung et al., 2013). Students use prescription stimulants to aid focus and
concentration, to work more efficiently, and to stay awake longer to study (Hartung et al., 2013).
A smaller percentage of individuals use prescription stimulants to (a) control appetite, (b) lose
weight, (c) improve athletic performance, (d) stay awake for non-academic reasons, or (e) “get
high” (Barrett, Darredeau, Bordy, & Pihl, 2005; Judson & Langdon, 2009; Varga, 2012).
Prescription stimulants are sometimes used as a substitute for recreational drugs that are more
expensive or difficult to obtain, such as cocaine or ecstasy (Barrett et al., 2005). They may also
be used in conjunction with other drugs. For example, prescription stimulants are sometimes
used to counteract the effects of depressant drugs, such as alcohol, or to intensify the effects of
other stimulant drugs, such as cocaine, ecstasy, or caffeine (Barrett et al., 2005).
Prevalence of prescription stimulant use in medical school. Although several studies
suggest that college students are at greatest risk for NMPSU, research indicates that this behavior
is also increasing among medical students (Emanuel et al., 2013; McNiel et al., 2011).
Approximately 8.4% of the total United States population and 4.4% of the adult population is
diagnosed with ADHD (Pilkinton & Cannatella, 2012). Therefore, it might be expected that
somewhere between 4.4% and 8.4% of medical students would hold a medical prescription for
stimulant drugs. However, individuals with ADHD tend to have lower educational attainment
than the general population, so the percentage of medical students who meet the criteria for
ADHD would actually be expected to be lower than in other populations (Low & Feldman,
2007). Despite these statistics, the number of medical students reporting prescription stimulant
use is considerably higher than in the general population (Wasserman et al., 2014). In a study of
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four Chicago-area medical schools, 18% of students reported lifetime use of prescription
stimulants and 11% reported use of prescription stimulants during medical school (Emanuel et
al., 2013). Similarly, when first- and second-year students were surveyed at a large school of
osteopathic medicine, 15.2% reported using prescription stimulants to help them study during
medical school (Wasserman et al., 2014). Yet another study found that 10% of students at an
allopathic medical school reported lifetime prescription stimulant use (Tuttle et al., 2010).
Recent research has also explored prescription stimulant use in graduate programs similar
to medical school, such as pharmacy and dental schools. In a study of two pharmacy programs in
North Carolina, 9% of students reported using prescription stimulants at least once during their
pharmacy education (Volger, McLendon, Fuller, & Herring, 2014). At a dental school in the
southern region of the United States, 12.4% of students reported NMPSU (McNiel et al., 2011).
Taken as a whole, these studies all suggest that students enrolled in medical school or similar
competitive graduate programs are at increased risk for NMPSU.
Despite recent efforts to assess NMPSU in medical students, it is difficult to distinguish
between medical and nonmedical prescription stimulant use in this population because of the
strong possibility that ADHD is being over-diagnosed. One study found that 72% of medical
students with ADHD were diagnosed after age 18, which raises questions about whether they
actually meet the criteria (Tuttle et al., 2010). On one hand, it is possible that these students had
mild symptoms and functioned well until academic or occupational demands exceeded their
coping skills. On the other hand, ADHD is classified as a developmental disorder in which the
onset of symptoms occurs before age 12. Late diagnosis suggests that an individual’s symptoms
might be better attributed to other factors, such as environmental stressors (Tuttle et al., 2010).
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Medical school may place individuals at risk for NMPSU for several reasons. First of all,
medical students tend to report significant academic pressure, stress, and feelings of competition
with their peers (Wasserman et al., 2014). In one study, the majority of medical students
reporting NMPSU stated that they used prescription stimulants for “academic improvement”
(Tuttle et al., 2010). Similarly, another study found that 70% of dental students with a history of
NMPSU used stimulants “to improve attention and/or concentration” (McNiel et al., 2011).
Additionally, medical students might be at higher at risk for NMPSU if they have easier access
to prescription stimulants or increased knowledge of the drugs’ effects.
Potential consequences of NMPSU. As with college students, medical students who use
prescription stimulants are more likely to report other types of drug use (Emanuel et al., 2013).
For example, one study found that prescription stimulant use during medical school is positively
correlated with ecstasy use (Emanuel et al., 2013). Similarly, a study of pharmacy students
indicated that students who report prescription stimulant use during pharmacy school are 4.5
times more likely to endorse other illicit drug use (Volger et al., 2014). As previously mentioned,
NMPSU also places individuals at risk for physical health consequences, including insomnia,
seizures, cardiovascular problems, and sudden death. Finally, medical students may experience
the same consequences of NMPSU as college students, including depression, anxiety, stress, and
lower grade point averages (Gomes et al., 2011; McCabe et al., 2005; Sussman et al., 2006).
Expectancy effects. Given the potential consequences of NMPSU, there have been
increasing efforts to understand and prevent this behavior in recent years. There is evidence that
individuals’ expectancies, or their expectations about a drug’s effects, can predict drug use
(Torrealday et al., 2008). According to expectancy theory, habits are created and maintained
when people predict that those behaviors will have positive consequences (Torrealday et al.,
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2008). Expectancies have been shown to predict many types of drug use, including marijuana,
cocaine, alcohol, and cigarette use (Torrealday et al., 2008). For example, positive expectations
for alcohol use are correlated with the age of onset and continuation of drinking (Torrealday et
al., 2008). Similarly, expectancies mediate the perceived effects of nicotine in individuals who
smoke cigarettes and predict feelings of alertness and calmness in those who ingest caffeine
(Kelemen, 2008; Schneider et al., 2006).
Several research efforts have focused on developing questionnaires to better understand
the types of expectancies that predict drug use. For example, the Marijuana Effect Expectancy
Questionnaire can be used to predict past and future marijuana use (Torrealday et al., 2008).
Looby and Earleywine (2009) developed the Prescription Stimulant Expectancy Questionnaire
(PSEQ) as a tool for assessing prescription stimulant use expectancies. The PSEQ originally
contained 40 items, including 20 designed to reflect positive expectancies and 20 designed to
reflect negative expectancies. Preliminary research on the PSEQ suggests that positive
expectancies, but not negative expectancies, predicted the frequency of prescription stimulant
use (Looby & Earleywine, 2009).
After gaining a better understanding of motives for prescription stimulant use through the
first study, Looby and Earleywine (2010) revised the test items to create the Prescription
Stimulant Expectancy Questionnaire–II (PSEQ–II). The PSEQ–II contains 11 new items that
reflect expectations related to mood and cognitive enhancement, both of which were commonly
expressed by participants in the earlier study (Looby & Earleywine, 2009).
In their study of adults in the general population, Looby and Earleywine (2010) identified
four factors that best account for variability in prescription stimulant use which they labeled:
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(a) Cognitive Enhancement, (b) Anxiety and Arousal (c) Social Enhancement, and (d) Guilt and
Dependence. The researchers then created composites of these factors to represent global
positive expectancies (Cognitive Enhancement and Social Enhancement) and global negative
expectancies (Anxiety and Arousal and Guilt and Dependence). The results of Looby and
Earleywine’s (2010) study suggest that the PSEQ–II can reliably discriminate among different
prescription stimulant user groups (i.e., nonusers, medical users, nonmedical users,
medical/nonmedical users) in the general population. Specifically, individuals who reported both
medical and nonmedical use of prescription stimulants reported the strongest positive
expectancies, while nonusers reported the weakest positive expectancies (Looby & Earleywine,
2010). In addition, research suggests that nonusers held the strongest negative expectancies while
medical users held the weakest negative expectancies (Looby & Earleywine, 2010).
Statement of the Problem
A major limitation of previous research on the PSEQ–II is that samples were comprised
largely of college students (Looby & Earleywine, 2009, 2010). Although college students are at
high risk for NMPSU, recent research suggests that medical students are also at increased risk
(Pilkinton & Cannatella, 2012; Emanuel et al., 2013; Wasserman et al., 2014; Volger et al.,
2014). The usefulness and applicability of the PSEQ–II to the medical student population has not
been assessed. Given that medical students may have more knowledge about prescription
stimulants and more exposure to them than the average person, their expectancies for
prescription stimulant use may be different (Wasserman et al., 2014). As such, their responses on
the PSEQ–II may not follow the same pattern found in previous studies, and their responses may
or may not be predictive of their prescription stimulant use habits. Considering the intense
cognitive demands and stress associated with medical school, it was predicted that expectancies

PRESCRIPTION STIMULANT USE AMONG MEDICAL STUDENTS

9

related to cognitive enhancement and anxiety and arousal would be most predictive of past
prescription stimulant use and plans for future use.
Purpose
The present study investigated the usefulness of the Prescription Stimulant Expectancy
Questionnaire–II (PSEQ–II) in identifying and classifying different types of prescription
stimulant users in the medical student population. Research suggests that the PSEQ–II can
reliably identify individuals at risk for NMPSU in the general population, but whether it can also
do so for the medical student population has not been determined (Looby & Earleywine, 2010).
If the PSEQ–II can predict the prescription stimulant use habits of medical students based on
their expectancies, it may be possible to intervene with problematic expectancies to reduce the
risk of NMPSU in this population (Looby & Earleywine, 2010; Looby, De Young, &
Earleywine, 2013). Based on previous research, reducing the rate of NMPSU among medical
students could also reduce their levels of stress, psychological symptoms, physical health
problems, and substance abuse (McCabe et al., 2005).
Research Questions
1. Can the PSEQ–II discriminate among prescription stimulant user types (e.g.,
nonusers, medical users, nonmedical users, medical/nonmedical users) in the medical
student population?
2. Can the PSEQ–II discriminate among prescription stimulant user types in the medical
student population when ADHD symptoms are controlled for?
3. What types of expectancies best predict medical students’ past prescription stimulant
use and plans for future use?
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4. Can positive and/or negative expectancies predict medical students’ past prescription
stimulant use and plans for future use?
Method
Participants
A total of 119 individuals participated in the study. Participants were individuals over the
age of 18 who were currently enrolled as full-time medical students in the United States.
Recreational users, medical users, and nonusers of prescription stimulants were all invited to
participate. Participants were recruited through Amazon Mechanical Turk, a website that allows
researchers to specify a specific population to sample. There is considerable disagreement
regarding the number of participants required for exploratory factor analysis, but several studies
suggest that 100 participants is an adequate sample size (Williams, Brown, & Onsman, 2012;
Costello & Osborne, 2005). Participants received $5 as compensation for completing the survey.
Procedure
Participants were able to access the survey website from any computer, which increased
confidentiality by allowing them to remain anonymous. Participants were then asked to complete
a background survey that included questions about demographic information and prescription
stimulant use history (See Appendix A). Specifically, participants were asked whether they had
ever in their lifetime used a prescription stimulant for any purpose. If so, they were asked
whether they had used the prescription stimulant for nonmedical purposes (i.e., taken a
prescription stimulant prescribed for someone else or taken a prescription stimulant not as
prescribed). Participants who reported lifetime use of prescription stimulants were asked whether
they had a valid prescription for the medication and their motives for use. Participants were also
asked to complete the 45-item Prescription Stimulant Expectancy Questionnaire–II (PSEQ–II)
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and an 18-item questionnaire assessing for symptoms of ADHD. The entire survey took
approximately 10 to 15 minutes to complete.
Prescription Stimulant Expectancy Questionnaire–II. The present study employed a
slightly shortened version of the PSEQ–II developed by Looby and Earleywine (2010; see
Appendix A). Looby and Earleywine both permitted the use of the PSEQ–II for my research (see
Appendix B). The PSEQ–II is a questionnaire that measures expectancy effects for prescription
stimulants among individuals with varying histories of prescription stimulant use. Participants
were asked to respond to each question on the PSEQ–II by indicating whether they would expect
to experience each effect when using a prescription stimulant. Although a 7-point Likert scale is
considered standard for most psychological studies, the PSEQ–II is formulated on a 3-point
Likert scale ranging from 0 (not at all) to 2 (very often or always).
The original PSEQ–II contains 51 items, but two items (“I focus on unimportant tasks”
and “I can’t focus on more than one thing at a time”) were removed from the questionnaire
because previous research indicated that they did not significantly load onto any factor (Looby &
Earleywine, 2010). In addition, four items (“I am more likely to use drugs and/or alcohol,” “I
don’t want to study/work without it,” “I get annoyed with myself for taking it,” and “I wish I
could do as well without it”) were removed because they cross-loaded onto multiple factors in
the previous study (Looby & Earleywine, 2010). Therefore, the present study employed a version
of the PSEQ–II with only 45 questions, which made the questionnaire somewhat less
burdensome for participants.
ADHD Symptoms Questionnaire. Participants were asked to complete an 18-item
questionnaire that assessed for symptoms for ADHD (Span, Earleywine, and Strybel, 2002; see
Appendix A). This questionnaire was selected by Looby & Earleywine (2010) over other

PRESCRIPTION STIMULANT USE AMONG MEDICAL STUDENTS

12

measures because of its reliability with the adult population and because it equally assesses
symptoms of inattention, hyperactivity, and impulsivity. Although the original ADHD
Symptoms Questionnaire uses a 7-point Likert scale, Looby and Earleywine (2010) used a
5-point Likert scale. In order to replicate their study as closely as possible, a 5-point Likert scale
ranging from 0 (never) to 4 (very often or always) was used. Keeping with the instructions of the
original study, participants who reported prescription stimulant use were asked to report how
they feel when not using prescription stimulants in order to best assess ADHD symptoms.
Statistical Analyses
All data were analyzed using SPSS for Windows. To understand the underlying factor
structure of the PSEQ–II, an exploratory factor analysis was conducted using principal axis
factoring. Once the factors were identified, they were assessed for internal consistency and
convergent validity. Multivariate analyses of variance (MANOVAs) were then conducted to
differentiate among prescription stimulant user types based upon these factors. Following the
MANOVAs, Roy Bargman stepdown analysis was employed to examine the differences among
factors. Scheffé post-hoc tests were then examined to determine the specific differences among
user types. Finally, multivariate analyses of covariance (MANCOVAs) were conducted to
examine factor differences while controlling for ADHD symptoms.
In order to assess what types of expectancies best predict prescription stimulant use in
medical students, multiple linear regressions were conducted. If the multivariate effect was
significant, the correlations between that factor and various indices of prescription stimulant use
(lifetime use, lifetime nonmedical use, use in the past three years, use in the past year, use in the
past three months, and plans for future use) were examined.
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Results
Descriptive Statistics
A total of 119 individuals participated in the study. Prior to data analyses, four
participants were eliminated from the sample because they indicated that they were not full-time
medical students. The resulting sample consisted of 115 participants: 67 male, 47 female, and
one participant who did not provide gender information. Thirty-five participants were between
the ages of 18 and 24, 74 were between the ages of 25 and 34, and 6 were 35 or older. Of those
sampled, 28 were in their first year of medical school, 53 were second-year students, 24 were
third-year students, one was a fourth-year student, six were completing internships, two were
completing residencies, and one was completing a fellowship.
Fifty-seven percent of those sampled (n = 66) reported lifetime prescription stimulant use
and 43% (n = 49) reported lifetime nonmedical use. Twenty-five percent indicated that they
might use prescription stimulants in the future and 34% indicated that they planned to do so. Of
those who endorsed past prescription stimulant use, the most commonly reported motivations
were to improve attention/concentration (n = 61), to work more efficiently (n = 54), and to stay
awake (n = 46). Less commonly reported motivations were to enhance exercise/athletic
performance (n = 8), to lose weight (n = 6), and to get high (n = 6). Users of prescription
stimulants scored an average of 48.78 on the ADHD symptom scale (SD = 14.39) and non-users
scored an average of 40.25 (SD = 9.81), which was significantly different (t(111) = 3.55, p <
.01).
Expectancy Scale Structure
To assess the underlying factor structure of the PSEQ–II, an exploratory factor analysis
was conducted using principal axis factoring with an oblique rotation (i.e., direct oblimin with
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Kaiser normalization). The Kaiser-Meyer-Olkin measure of sampling adequacy and Bartlett’s
test of sphericity were examined to determine whether or not the data was factorable. The
Kaiser–Meyer–Olkin measure was greater than .6 and Bartlett’s test of sphericity was less than
.001, suggesting that the correlation matrix was not an identity matrix and that the data was
likely factorable. Next, the scree plot was examined to determine the number of valid factors.
According to Tabachnick and Fidell (2007, as cited by Looby & Earleywine, 2010), the point at
which the slope changes corresponds to the valid number of factors. The slope of the scree plot
suggested that there were four valid factors.
A second EFA was then conducted to force exactly four factors. Variables were defined
as within a factor if they were greater than |.32| using the pattern matrix (Tabachnick & Fidell,
2007 as cited by Looby & Earleywine, 2010). Using this criterion, four items failed to load onto
a factor (“I absorb material the first time through,” “I feel like I can’t get through the day without
it,” “It’s no trouble to sit still,” and “I get nervous and edgy”). In addition, five factors
cross-loaded onto multiple factors (“I can ignore distractions more easily,” “I feel drained the
next day,” “I feel like I’m cutting corners to do well,” “I’m all amped up,” and “I feel more
confident in myself”). A third EFA was then conducted with these items removed. In examining
this EFA, no items loaded onto the fourth factor, so a fourth and final EFA was conducted to
force exactly three factors.
Table 1 shows the Eigenvalues and explained variance for each of the factors from the
final analysis. Factor 1 consisted of items related to enhanced concentration and cognitive skills
(e.g., “I can pay attention really well”) and was labeled “Cognitive Enhancement” (see Table 2).
Factor 2 consisted of items related to negative physiological symptoms (e.g., “I feel twitchy”)
and was labeled “Anxiety and Arousal” (see Table 3). Factor 3 consisted of items related to
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improved social abilities (e.g., “Conversing with others is easier”) and was labeled “Social
Enhancement” (see Table 4). All three factors had good internal consistency. Cronbach’s alphas
were .94 for Factor 1, .88 for Factor 2, and .80 for Factor 3.
Research Question 1
To assess whether the PSEQ–II could discriminate among prescription stimulant user
types, participants were classified into four groups based on past prescription stimulant use:
(a) non-users (n = 49), (b) nonmedical users (n = 3), (c) medical users (n = 15), and
(d) medical/nonmedical users (n = 46). Of note, two individuals could not be classified because
they endorsed past prescription stimulant use, but denied using them for either medical or
nonmedical purposes. Additionally, given that only three respondents could be classified as
exclusively nonmedical users, this group was not included in analyses comparing user groups.
One-way ANOVAs were performed to examine any differences in age, gender, or school
year among user groups. No significant differences in age (x2 = 1.46, p = .521), gender (x2 = .02,
p = .92), or school year (x2 = 1.95, p = .66) were observed among user groups.
A MANOVA was then conducted to examine factor scale differences among user groups
(see Table 5). Using Pillai’s Trace, the multivariate effect for user type was significant (F(6, 212)
= 5.25, p < .001) and significant differences were observed among user groups on the Cognitive
Enhancement factor (F(2, 109) = 10.23, p < .001) and the Anxiety and Arousal factor (F (2, 109)
= 8.55, p < .01). No significant differences were found among user groups on the Social
Enhancement factor (F (2, 109) = 1.90, p = .16).
Sheffé post-hoc tests were then used to evaluate the differences among user types for
each factor (see Table 5). On the Cognitive Enhancement scale, nonusers scored significantly
lower than medical users or medical/nonmedical users. Medical users held the strongest beliefs
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about cognitive enhancement, followed by medical/nonmedical users and nonusers respectively.
On the Anxiety and Arousal scale, nonusers scored significantly higher than medical users or
medical/nonmedical users, with nonusers holding the most beliefs, followed by medical users
and medical/nonmedical users respectively. On the Social Enhancement scale, none of the
groups significantly differed from one another.
Research Question 2
To further clarify the relationship between expectancies and user type, a MANCOVA
was conducted while controlling for ADHD symptoms (see Table 6). Controlling for ADHD
symptoms did not change the relationship between PSEQ–II factors and user type. Using Pillai’s
Trace, the multivariate effect among groups remained significant (F(6, 206) = 5.63, p < .001).
Furthermore, the effects for the Cognitive Enhancement factor (F(2, 108) = 8.43, p < .001) and
the Anxiety and Arousal factor (F(2, 108) = 12.74, p < .001) remained significant. There was
still no significant effect for the Social Enhancement factor (F(2, 108) = .88, p = .42).
Research Question 3
In order to assess what types of expectancies best predict prescription stimulant use in
medical students, multiple linear regressions were conducted. The multivariate effect for
Cognitive Enhancement was significant (R2 = .26, F(7, 114) = 5.23, p < .001). The correlations
between Cognitive Enhancement and prescription stimulant use (lifetime use, lifetime
nonmedical use, use in the past three years, use in the past year, use in the past three months, and
plans for future use) were then examined. Cognitive Enhancement significantly predicted use in
the past three months (b = .45, t(108) = 2.52, p < .05).
The multivariate effect for Anxiety and Arousal and prescription stimulant use was also
significant (R2 = .20, F(7, 114) = 3.72, p < .01). When the correlations between Anxiety and
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Arousal and various indices of use were examined (see Table 8), Anxiety and Arousal was
significantly predictive of lifetime use (b = -.51, t(108) = -2.24, p < .05) and use in the past
month (b = -.28, t(108) = -2.20, p < .05).
The multivariate effect for Social Enhancement and prescription stimulant use was not
significant (R2 = .11, F(7, 114) = 1.82, p = .90).
Research Question 4
To examine positive and negative expectancies more generally, a global positive scale
was created by combining the Cognitive Enhancement factor and the Social Enhancement factor.
The multivariate effect among indices of use was significant (R2 = .21, F(7, 114) = 5.25, p <
.001). When the correlations between Positive Expectancies and various indices of use were
examined (see Table 9), the Positive Expectancies scale was significantly predictive of use in the
past three months (b = .56, t (114) = 3.08, p < .005).
As previously mentioned, the Anxiety and Arousal factor, which represented negative
expectancies, was also significantly predictive of prescription stimulant use (R2 = .20, F(7, 114)
= 3.72, p < .01). More specifically, Anxiety and Arousal was significantly predictive of lifetime
use (b = -.51, t(108) = -2.24, p < .05) and use in the past month (b = -.28, t(108) = -2.20, p < .05).
Discussion
PSEQ–II Factor Structure
In terms of the underlying factor structure of the PSEQ–II, the present results differ
slightly from earlier findings in that three factors were observed, rather than four. However, the
factors themselves are consistent with those found by Looby and Earleywine (2010).
Specifically, factors related to (a) cognitive enhancement, (c) social enhancement, and
(c) anxiety and arousal were identified.
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The fact that there was no factor for guilt and dependence suggests that participants
responded inconsistently to items related to this topic. One possible explanation for this finding
is that medical students might feel more ambivalence about prescription stimulant use than the
general population. In other words, they might feel somewhat guilty about using prescription
stimulants, but they might also believe that their use is justified. Previous research indicates that
people feel less guilty about using prescription stimulants if they can mentally justify it (Judson
& Langdon, 2009). Given the cognitive demands, stress levels, and competitive nature of
medical school (Wasserman et al., 2014), it is easy to imagine how medical students might
justify their use.
It is also possible that medical students have different knowledge of prescription
stimulant effects than the average person, leading them to discriminate among various
dependency effects more than a layperson. For example, the average college student might
endorse global, generalized expectations of dependence, whereas a medical student might
believe that certain dependency symptoms are more likely than others.
Finally, it is worth noting that the original Guilt and Dependency factor was the weakest
and least predictive of the four factors identified by Looby and Earleywine (2010). In the
aforementioned study, Guilt and Dependence explained just 2.83% of the variance among
PSEQ–II items in comparison to the 24.63% explained by the Cognitive Enhancement factor.
Therefore, the present findings are probably not an extreme departure from earlier findings.
Furthermore, the original Guilt and Dependence factor consisted of just five items. Of these
items, two were removed from the present study prior to the final factor analysis because they
either failed to load onto a factor (“I feel like I can’t get through the day without it”) or
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cross-loaded onto multiple factors (“I feel like I’m cutting corners to do well”). The removal of
these items likely contributed to the disappearance of this factor from the factor analysis.
Ability to Discriminate Among User Types
Users versus nonusers. The present results support previous findings that the PSEQ–II
can effectively discriminate among certain prescription stimulant user types. As suggested by
Looby & Earleywine (2010), nonusers appear to hold the strongest beliefs about anxiety and
arousal and the weakest beliefs about cognitive enhancement (Looby & Earleywine, 2009,
2010).
Conceptually, these findings are logical for several reasons. First of all, individuals who
do not expect cognitive benefits would have less motivation to use prescription stimulants than
individuals who expect such effects. Similarly, individuals who expect to feel anxious or
physiologically aroused would probably be more likely avoid prescription stimulant use. An
alternative explanation is that nonusers had never considered negative side effects, but endorsed
them during the study as a way of mentally justifying why they had not used prescription
stimulants. If nonusers endorsed expectations about cognitive enhancement, which they did to
some degree, but not anxiety and arousal, it would have left them with a sense of cognitive
dissonance. In other words, if they expected prescription stimulants to have positive effects, but
not negative effects, they might have questioned why they had never tried them. In the same
way, medical and medical/nonmedical users might have exaggerated their beliefs about cognitive
enhancement and downplayed their beliefs about anxiety and arousal in order to minimize
cognitive dissonance about using them. Finally, it is possible that medical and
medical/nonmedical users legitimately experience cognitive enhancement without anxiety or
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arousal. Nonusers might hold different beliefs about these effects simply because they have
never tried them.
Medical users versus medical/nonmedical users. While the PSEQ–II was effective at
discriminating prescription stimulant users from nonusers, it was not effective at distinguishing
medical users from medical/nonmedical users. Thus, Looby and Earleywine’s (2010) findings do
not completely generalize to the medical student population. Among medical students, medical
users and medical/nonmedical users did not significantly differ from one another in terms of their
expectancies about either cognitive enhancement or anxiety and arousal.
There are several possible explanations for this discrepancy. First, it is possible that
medical and medical/nonmedical users do not significantly differ in terms of their prescription
stimulant use expectancies, which would make the PSEQ–II ineffective at distinguishing
between these two groups. Perhaps medical students’ experience with prescription stimulants,
combined with their knowledge of drug effects, causes them to hold expectancies that are
relatively similar to one another. Alternatively, the two user groups might hold expectancies that
were not adequately assessed by the PSEQ–II (i.e., unrelated to cognitive enhancement, social
enhancement, anxiety and arousal, or guilt and dependence). There might be a different category
of beliefs or a different way of wording those items that would be more relevant to medical
students. Finally, it is possible that the PSEQ–II could not discriminate between medical users
and medical/nonmedical users because of how these constructs were defined. To the extent that
ADHD is over-diagnosed in the medical student population, the line between medical and
nonmedical use is somewhat unclear. As previously mentioned, ADHD is estimated to occur in
4.4% of adults in the United States (Pilkinton & Cannatella, 2012), but an overwhelming 53% of
medical students sampled in the present study reported lifetime possession of a prescription for
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stimulants. As such, participants might have classified their use as medical because they took
their medications as prescribed. However, if they should not have been diagnosed with ADHD in
the first place, it raises questions about whether their use should truly be considered medical.
Although the ADHD Symptom Questionnaire can help by clarifying the extent of ADHD
symptoms, the presence of symptoms alone does not necessarily warrant a diagnosis or medical
prescription. Many typically developing individuals experience problems with concentration,
restlessness, and forgetfulness when placed in stressful environments or when deprived of sleep.
As such, some level of these symptoms might be expected of medical students, even if they did
not have ADHD. In addition, it is possible that medical students’ self-reports were not an
accurate reflection of their true symptom presentation. For example, medical students might have
exaggerated their reporting of ADHD symptoms in order to reduce cognitive dissonance about
prescription stimulant use. Alternatively, they might perceive that average levels of attention and
concentration are abnormal because they are surrounded by high-achieving peers.
Ability to Predict Prescription Stimulant Use
The present study’s results support earlier findings that the PSEQ–II can predict past
prescription stimulant use (Looby & Earleywine, 2009). Specifically, the Cognitive
Enhancement and Positive Expectancies scales were predictive of use in the past three months.
In contrast to earlier findings, the Anxiety and Arousal scale was also predictive of lifetime
prescription stimulant use and use in the past month. Specifically, individuals with stronger
expectancies related to anxiety and arousal were less likely to report past prescription stimulant
use. One possible explanation for this discrepancy is a difference in methodology. Looby and
Earleywine (2009) assessed the frequency of past prescription stimulant use, whereas the present
study investigated the presence or absence of use across different time periods (i.e., lifetime use,
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lifetime nonmedical use, use in the past three years, use in the past year, use in the past three
months, use in the past month). Therefore, negative expectancies might predict the presence or
absence of past use, or the recency of such use, but not the frequency. It is also possible that
negative expectancies predict prescription stimulant use among medical students, but not
members of the general population. This could be due to factors that differentiate medical
students from the general population, such as higher levels of stress and anxiety, reduced sleep,
or increased knowledge of medication effects.
The present study also extended previous research by investigating plans for future use.
The results suggest that the PSEQ–II is not predictive of medical students’ plans for future use.
However, it does appear to predict medical students’ lifetime use, use in the past three months,
and use in the past month, any of which might be correlated with future use.
Prevalence of Prescription Stimulant Use Among Medical Students
Of the medical students who participated in the present study, 57% reported lifetime
prescription stimulant use and 43% endorsed lifetime NMPSU. These rates exceed those
reported in earlier studies of this population. On one hand, the present results might be an
overestimate of prescription stimulant use. It is possible that individuals with a history of
prescription stimulant use were more interested in the study and therefore more inclined to
participate. On the other hand, these rates might reflect a legitimate increase in prescription
stimulant use over the past few years. The rates of ADHD diagnosis and prescription stimulant
treatment continue to increase steadily, especially among college students (Bavarian et al., 2013;
Varga, 2012). If the demands of college remain the same or increase in medical school, one
might expect that students who used prescription stimulants in college would continue to do so in
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medical school. Additionally, students who refrained from using prescription stimulants in
college might begin doing so in medical school if the demands increase.
Finally, it is possible that the present findings are actually an underestimate of NMPSU in
this population. If ADHD is being over-diagnosed in this population, then perhaps some of this
prescription stimulant use should not be considered medical. Even when nonmedical users are
excluded from the equation, the fact that 14% of participants were classified as medical users is
concerning. It is possible that all of these students were honest with their prescribers and
legitimately believed that they had ADHD. However, the comparatively high rate of ADHD
diagnosis in this population suggests that psychiatrists and medication providers should be
cautious when assessing this population.
Limitations
It is important to consider several potential limitations of this study. First, the data
consisted of anonymous self-reports. Participants’ responses may have been biased if they were
motivated by monetary gain. For example, they might have responded quickly and randomly
with the sole goal of monetary acquisition. Additionally, they might have responded in a way
that they hoped would be consistent with the researcher’s preferences, in order to insure that they
would be rewarded for their time. Furthermore, the anonymous nature of the survey might have
contributed to reduced feelings of personal responsibility, allowing participants to respond more
randomly or less truthfully. Another limitation of this study is the exclusion of exclusively
nonmedical users from analyses. However, it is possible that exclusively nonmedical users are
rare within the medical student population, which would make examining this group less
meaningful or urgent. Finally, another limitation of this study is that it examined prescription
stimulant use across various time frames, but did not investigate the frequency of such use. It is
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possible that information about frequency would enhance understanding about the PSEQ–II’s
applicability to the medical student population. For the sake of prevention and intervention
efforts, it would be useful to understand how often medical students use prescription stimulants.
Conclusions and Directions for Future Research
Taken as a whole, the number of medical students who indicated that they might use
(25%) or planned to use (34%) prescription stimulants in the future is alarming. Nonmedical
prescription stimulant use is associated with a number of negative outcomes, including lower
grade point averages and increased rates of drug and alcohol abuse, mental illness, and physical
health problems (Emanuel et al., 2013; McCabe et al., 2005; Volger et al., 2014). Fortunately,
the present findings should be useful in informing future research and intervention efforts for this
population. In general, medical students appear to be at greater risk for prescription stimulant use
if they hold strong expectancies related to cognitive enhancement and weak expectancies related
to anxiety and arousal. Therefore, future research should explore interventions that alter these
beliefs. For example, practitioners might challenge these beliefs through cognitive-behavioral
therapy or Motivational Interviewing. Researchers might also explore the usefulness of
psychoeducation in encouraging more realistic or safe beliefs about prescription stimulants.
Given the prevalence of prescription stimulant use among medical students, medical schools
should consider implementing widespread preventative and intervention efforts of their own.
Finally, medical providers should be educated about the prescription stimulant use habits of
medical students and adopt a careful, conservative attitude when diagnosing ADHD or
prescribing stimulants to members of this population.
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Note. Following the PSEQ–II, participants completed the ADHD Symptoms Questionnaire
derived from Span, Earleywine, and Strybel (2002). These items are not included here because
permission was not obtained.
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Table 1
Eigenvalues and Explained Variance of PSEQ–II Factors
Factor

Eigenvalue

Explained Variance

Factor 1 – Cognitive Enhancement

9.49

26.37%

Factor 2 – Anxiety and Arousal

5.00

13.90%

Factor 3 – Social Enhancement

2.96

8.22%
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Table 2
Factor Loadings for Cognitive Enhancement Factor
PSEQ–II Item

Factor Loading

22. Distractions disappear

.58

26. I can pay attention really well

.77

27. I can study/work for hours

.61

31. I don’t end up daydreaming

.40

32. I enjoy studying/work a lot more

.51

40. I learn/work very efficiently

.74

41. I need fewer breaks when I study/work

.81

46. My ability to focus is better

.89

47. My concentration is excellent

.88

48. My focus is crystal clear

.75

51. My mind doesn’t wander

.62

52. My mind is razor sharp

.78

53. My thoughts follow more logically

.51

57. I can focus really well

.72

62. My memory is better

.64

65. My thoughts stay on track better

.78
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Table 3
Factor Loadings for Anxiety and Arousal Factor
PSEQ–II Item

Factor Loading

28. I can’t hold still

.52

29. I can’t sleep even if I want to

.52

37. I feel sick to my stomach

.54

38. I feel high

.50

42. I worry that I’m addicted to it

.72

45. I’ve come to see it as a crutch

.61

49. My head hurts

.65

56. My heart races

.76

58. I can’t calm down

.71

59. I feel twitchy

.72

63. I feel guilty for taking it

.63
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Table 4
Factor Loadings for Social Enhancement Factor
PSEQ–II Item

Factor Loading

24. I feel very happy

.51

30. I enjoy parties more

.53

34. Conversing with others is easier

.62

39. I am friendlier

.60

50. I’m free to be myself and do whatever I want to do

.51

54. I feel more relaxed in social situations

.59

55. My work seems more interesting

.43

60. I feel as though everything is right in the world

.48

66. I laugh more

.68
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Table 5
Mean Differences in Factor Scale Scores Among User Groups
Group 1

Group 2

Group 3

(Medical/Nonmedical)

(Medical Users)

(Nonusers)

Factor

M

SD

M

SD

M

SD

F(2, 109)

p value

Post-Hoc Tests

Cognitive

40.37

5.44

40.93

5.71

34.86

7.59

10.23

.000*

1, 2>3

Anxiety

18.26

4.58

18.27

3.90

21.96

4.93

8.55

.000*

1, 2<3

Social

18.33

3.56

17.73

3.79

16.81

3.99

1.90

.155

Note. * Correlation is significant at the .001 level (2-tailed).
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Table 6
Mean Differences in Factor Scale Scores Among User Groups while Controlling for ADHD
Group 1

Group 2

Group 3

(Medical/Nonmedical)

(Medical Users)

(Nonusers)

Factor

M

SD

M

SD

M

SD

F(2,108)

p value

Post-Hoc Tests

Cognitive

40.44

5.48

40.93

5.71

34.64

7.53

8.43

.000*

1, 2>3

Anxiety

18.00

4.27

18.27

3.90

21.94

4.98

12.74

.000*

1, 2<3

Social

18.47

3.47

17.73

3.79

16.73

3.99

.876

.42

Note. * Correlation is significant at the .001 level (2-tailed).
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Table 7
Standardized Beta Weights, t values, and p values for Cognitive Enhancement Factor
Index of Use

b

All indices of use

t

p

18.938

.000**

Lifetime use

.21

.97

.34

Lifetime nonmedical use

.22

1.48

.14

Use in the past three years

.13

.68

.50

Use in the past year

.04

.16

.87

Use in the past three months

.45

2.52

.01*

Use in the past month

.08

.68

.50

Plans for future use

.06

.53

.60

Note. * Correlation is significant at the .05 level (2-tailed). ** Correlation is significant at the
.001 level (2-tailed).
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Table 8
Standardized Beta Weights, t values, and p values for Anxiety and Arousal Factor
Index of Use

b

All indices of use

t

p

8.88

.000**

Lifetime use

.51

2.24

.03*

Lifetime nonmedical use

.18

1.12

.29

Use in the past three years

.22

1.08

.21

Use in the past year

.34

1.27

.91

Use in the past three months

.02

.16

.03*

Use in the past month

.28

2.20

.27

Plans for future use

.11

.89

.37

Note. * Correlation is significant at the .05 level (2-tailed). ** Correlation is significant at
the .001 level (2-tailed).
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Table 9
Standardized Beta Weights, t values, and p values for Positive Expectancies Factor
Index of Use

b

All indices of use

t

p

20.77

.000**

Lifetime use

.30

1.38

.17

Lifetime nonmedical use

.25

1.64

.10

Use in the past three years

.08

.40

.69

Use in the past year

.13

.51

.62

Use in the past three months

.56

3.08

.003*

Use in the past month

.01

.04

.97

Plans for future use

.08

.67

.50

Note. * Correlation is significant at the .005 level (2-tailed). ** Correlation is significant at the
.001 level (2-tailed).

